News
Nature Biotechnology 25, 365 - 366 (2007)
Published online: 3 April 2007 | doi:10.1038/nbt0407-365
Pharma consolidates its grip on post-antibody landscape
Cormac Sheridan1
- Dublin
Abstract
The next wave of protein therapeutics, based on non-traditional scaffolds, may offer advantages in the range of conditions they can treat, delivery, and manufacturing. But they are just beginning to prove themselves in the clinic.
